[干扰素λ作为严重急性呼吸综合征冠状病毒2抑制剂的潜力]

[Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2].

作者信息

Oleinik L A, Madonov P G, Pykhtina M B

机构信息

Research Institute of Clinical and Experimental Lymphology-Branch of Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090 Russia.

出版信息

Mol Biol (Mosk). 2023 Mar-Apr;57(2):307-315.

PMID:37000658

Abstract

This study provides an overview of scientific results on the feasibility of using type III interferons against SARS-CoV-2. We have analyzed data obtained from the PubMed electronic database for the period 2020-2022. The results of our own studies of pharmacological substances based on recombinant IFN-λ1 and its pegylated form are also presented. Completed and ongoing investigations allow us to position IFN-λ as an effective therapeutic agent against SARS-CoV-2.

摘要

本研究概述了使用III型干扰素对抗新型冠状病毒（SARS-CoV-2）的可行性的科学成果。我们分析了从2020年至2022年期间的PubMed电子数据库中获得的数据。我们还展示了基于重组干扰素λ1及其聚乙二醇化形式的药理物质的自身研究结果。已完成和正在进行的研究使我们能够将干扰素λ定位为对抗SARS-CoV-2的有效治疗剂。